Evidence map›Paper›PMID 34295677›Full record

ReviewTranslational lung cancer research2021

Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer.

Steven Bozinovski, Amanda Vannitamby, Kanishka Rangamuwa, Savreet Aujla, Hao Wang, Christian Aloe, Louis Irving, Tracy T Leong, Daniel P Steinfort

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Frontiers in oncology · 2022
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Steven BozinovskiSchool of Health & Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.
Amanda VannitambySchool of Health & Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.
Kanishka RangamuwaDepartment of Respiratory Medicine, Royal Melbourne Hospital, Melbourne, Australia.
Savreet AujlaSchool of Health & Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.
Hao WangSchool of Health & Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.
Christian AloeSchool of Health & Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.
Louis IrvingDepartment of Respiratory Medicine, Royal Melbourne Hospital, Melbourne, Australia.
Tracy T LeongDepartment of Respiratory Medicine, Austin Health, Heidelberg, Victoria, Australia.
Daniel P SteinfortDepartment of Respiratory Medicine, Royal Melbourne Hospital, Melbourne, Australia.
RMIT University · AUThe Royal Melbourne Hospital · AUUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy has transformed treatment of advanced non-small-cell lung cancer (NSCLC) patients leading to remarkable long-term survival benefit. However, only about 20% of advanced NSCLC patients typically respond to immune checkpoint inhibitors (ICIs) that target the PD-1/PD-L1 pathway. The only validated biomarker for ICI therapy is the PD-L1 immunohistochemistry (IHC) test, which is considered an imperfect assay due to several variables including availability and integrity of tumour tissue, variability in staining/scoring techniques and heterogeneity in PD-L1 protein expression within and across tumour biopsies. Herein, we discuss integrating minimally invasive EBUS bronchoscopy procedures with novel molecular approaches to improve accuracy and sensitivity of PD-L1 testing. EBUS guided bronchoscopy facilitates repeated sampling of tumour tissue to increase the probability of detecting PD-L1 positive tumours. Since intra-tumoural

Indexed as

biomarkersbronchoscopyImmunotherapylung cancernon-small cell lung cancer (NSCLC)programmed death Inhibitor 1 ligand (PD-L1)

Identifiers

PMID34295677
PMCPMC8264344
OpenAlexW3084152484

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.